공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

중국의 파클리탁셀(Paclitaxel) 시장에 관한 조사보고서(2021-2025년)

Investigation Report on China´s Paclitaxel Market 2021-2025

리서치사 China Research and Intelligence
발행일 2021년 05월 상품 코드 1008262
페이지 정보 영문 50 Pages
가격
US $ 2,600 ₩ 3,093,000 Unprintable PDF (Single User License)
US $ 3,900 ₩ 4,640,000 Printable & Editable PDF (Enterprisewide License)


중국의 파클리탁셀(Paclitaxel) 시장에 관한 조사보고서(2021-2025년) Investigation Report on China´s Paclitaxel Market 2021-2025
발행일 : 2021년 05월 페이지 정보 : 영문 50 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

중국 시장에서의 파클리탁셀 판매량은 2016년부터 2019년까지 해마다 증가했습니다. 2018년 21억 6,800만 위안에서 2019년에는 30억 5,300만 위안으로 증가했고, 연간 성장률은 40.86%로 가장 높아졌습니다. 2016-2020년간 중국 시장의 파클리탁셀 매출은 7.16%의 연평균 복합 성장률(CAGR)로 증가했고, 2020년 통합 조달에 의한 급격한 가격 인하에 의해 파클리탁셀 매출은 -18.64%의 성장률로 감소했습니다.

중국에서의 파클리탁셀 판매량은 2021-2025년간 유방암 환자가 증가함에 따라 꾸준히 증가할 것으로 예상됩니다. 2020년에는 세계 유방암 신규 확진자가 226만명에 달했고, 유방암이 가장 일반적으로 진단되는 암으로 폐암의 증례수를 넘어섰습니다. 따라서, 유방암 치료용 파클리탁셀 매출 및 판매량은 진단 환자수가 증가함에 따라 증가할 전망입니다. 또한 파클리탁셀은 2021년 전국 약가 교섭에 포함되어 있어서 앞으로도 판매량은 지속적으로 증가할 것으로 예측됩니다.

중국의 파클리탁셀(Paclitaxel) 시장에 대해 조사했으며, 시장 규모와 예측, 동향, COVID-19에 의한 영향, 가격, 성장요인과 기회, 위협, 과제, 시장 점유율 등의 정보를 제공합니다.

목차

제1장 파클리탁셀 관련 개념

  • 파클리탁셀의 적응증
  • 중국에서의 파클리탁셀 개발
  • 중국 정부의 파클리탁셀 승인
  • COVID-19가 중국의 파클리탁셀 판매에 미치는 영향

제2장 중국에서의 파클리탁셀 판매(2016-2020년)

  • 파클리탁셀 매출
    • 총 매출
    • 지역별 매출
  • 파클리탁셀 판매량
    • 총 판매량
    • 지역별 판매량
  • 중국의 제형별 파클리탁셀 판매(2016-2020년)
    • 리포솜 주입
    • 주입(나노입자 알부민 결합)
    • 주입
    • 기타 제형 분석

제3장 중국의 주요 파클리탁셀 제조업체 분석(2016-2020년)

  • 주요 파클리탁셀 제조업체의 시장 점유율 분석
    • 매출별 시장 점유율 조사
    • 판매량별 시장 점유율 조사
  • Nanjing Luye Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 LIPOSOME (Nanjing Luye Pharmaceutical Co., Ltd.'s Paclitaxel) 판매
  • CSPC Ouyi Pharmaceutical Group Co., Ltd.
    • 기업 개요
    • 중국에서의 Aiyue (Jiangsu Hengrui Pharmaceutical Co., Ltd.'s Paclitaxel) 판매
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 APaclitaxel (Hospira Australia Pty Ltd's Paclitaxel) 판매
  • Hospira Australia Pty Ltd
    • 기업 개요
    • 중국에서의 Paclitaxel (Hospira Australia Pty Ltd's Paclitaxel) 판매
  • Beistol-Myers Squibb Srl
    • 기업 개요
    • 중국에서의 TAXOL(Beistol-Myers Squibb Srl's Paclitaxel) 판매

제4장 중국 제조업체의 파클리탁셀 가격(2020-2021년)

  • Nanjing Luye Pharmaceutical Co., Ltd.(LIPOSOME)
  • CSPC Ouyi Pharmaceutical Group Co., Ltd.(Keaili)
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.(Aiyue)
  • Hospira Australia Pty Ltd(ANZATAX)
  • Beistol-Myers Squibb S.r.l.(TAXOL)

제5장 중국의 파클리탁셀 시장 전망(2021-2025년)

  • 중국 파클리탁셀 시장 발전의 영향력 있는 요인
    • 중국 파클리탁셀 시장에 대한 COVID-19의 영향
    • 시장 성장요인과 기회
    • 시장 위협과 과제
  • 시장 규모 예측
  • 시장 동향 예측
LSH 21.06.22

List of Charts

  • Chart Patent Information About Paclitaxel Liposome Injection Registration in China
  • Chart Patent Information About Paclitaxel (Nanoparticle Albumin-bound) Injection Registration in China
  • Chart Patent Information About Paclitaxel Injection Registration in China
  • Chart Sales Value of Paclitaxel Liposome Injection over the World   
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) over the World
  • Chart Sales Value of Paclitaxel Injection over the World
  • Chart Sales Value of Paclitaxel Liposome Injection in China, 2016-2020  
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020
  • Chart Sales Value of Paclitaxel Injection in China, 2016-2020
  • Chart Sales Value of Paclitaxel Liposome Injection in China by Regions, 2016-2020
  • Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020
  • Chart Sales Value of Paclitaxel Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Liposome Injection in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection in China, 2016-2020
  • Chart Sales Volume of Paclitaxel Liposome Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020
  • Chart Sales Volume of Paclitaxel Injection in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of LIPOSOME in China, 2016-2020
  • Chart Sales Value and Volume of Keaili in China, 2016-2020
  • Chart Sales Value and Volume of Aiyue in China, 2016-2020
  • Chart Sales Value and Volume of ANZATAX in China, 2016-2020
  • Chart Sales Value and Volume of TAXOL in China, 2016-2020        
  • Chart Referential Prices of LIPOSOME in China by Regions, 2020-2021        
  • Chart Referential Prices of Keaili in China by Regions, 2020-2021
  • Chart Referential Prices of Aiyue in China by Regions, 2020-2021     
  • Chart Referential Prices of ANZATAX in China by Regions, 2020-2021          
  • Chart Referential Prices of TAXOL in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Liposome Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Injection (Nanoparticle Albumin-bound) in China, 2021-2025
  • Chart Forecast on Sales Value of Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Liposome Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Injection (Nanoparticle Albumin-bound) in China, 2021-2025
  • Chart Forecast on Sales Volume of Injection in China, 2021-2025

Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy. Its product, developed by Abolis, was approved by the FDA in 2005 and was approved in China in 2008. By 2020, there are 34 manufacturers in the Chinese Paclitaxel market, with Nanjing Luye Pharmaceutical Co., Ltd. accounting for the most market share in the Chinese Paclitaxel market.

According to CRI analysis, the sales of Paclitaxel in the Chinese market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital's overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers. With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.

CRI analyzes that the Paclitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer. Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.

Topics Covered:

  • The impact of COVID-19 on China's Paclitaxel market
  • Sales value of China's Paclitaxel 2016-2020
  • Competitive landscape of China's Paclitaxel market
  • Prices of Paclitaxel in China
  • Prices of Paclitaxel in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Paclitaxel market
  • Prospect of China's Paclitaxel market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Paclitaxel       

  • 1.1 Indications for Paclitaxel       
  • 1.2 Development of Paclitaxel in China
  • 1.3 Governmental Approval of Paclitaxel in China
  • 1.4 The Impact of COVID-19 on Paclitaxel sales in China

2 Sales of Paclitaxel in China, 2016-2020   

  • 2.1 Sales Value of Paclitaxel
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Paclitaxel     
    • 2.2.1 Overall Sales Volume  
    • 2.2.2 Sales Volume by Regions    
  • 2.3 Sales of Paclitaxel by Dosage Form in China, 2016-2020    
    • 2.3.1 Liposome injection
    • 2.3.2 Injection (nanoparticle albumin-bound)
    • 2.3.3 Injection
    • 2.3.4 Analysis of Other Dosage Forms

      

3 Analysis of Major Paclitaxel Manufacturers in China, 2016-2020   

  • 3.1 Analysis of Market Share of Major Paclitaxel Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value    
    • 3.1.2 Investigation on Market Share by Sales volume 
  • 3.2 Nanjing Luye Pharmaceutical Co., Ltd. 
    • 3.2.1 Enterprise Profile 
    • 3.2.2 Sales of LIPOSOME (Nanjing Luye Pharmaceutical Co., Ltd.'s Paclitaxel) in China

3.3  CSPC Ouyi Pharmaceutical Group Co., Ltd.

    • 3.3.1 Enterprise Profile 
    • 3.3.2 Sales of Keaili (CSPC Ouyi Pharmaceutical Group Co., Ltd.'s Paclitaxel) in China
  • 3.4 Jiangsu Hengrui Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile 
    • 3.4.2 Sales of Aiyue (Jiangsu Hengrui Pharmaceutical Co., Ltd.'s Paclitaxel) in China
  • 3.5 Hospira Australia Pty Ltd
    • 3.5.1 Enterprise Profile 
    • 3.5.2 Sales of Paclitaxel (Hospira Australia Pty Ltd's Paclitaxel) in China
  • 3.6 Beistol-Myers Squibb S.r.l.
    • 3.6.1 Enterprise Profile 
    • 3.6.2 Sales of TAXOL (Beistol-Myers Squibb S.r.l.'s Paclitaxel) in China

4 Prices of Paclitaxel for Different Manufacturers in China, 2020-2021

  • 4.1 Nanjing Luye Pharmaceutical Co., Ltd. (LIPOSOME) 
  • 4.2 CSPC Ouyi Pharmaceutical Group Co., Ltd. (Keaili)
  • 4.3 Jiangsu Hengrui Pharmaceutical Co., Ltd. (Aiyue)
  • 4.4 Hospira Australia Pty Ltd (ANZATAX)
  • 4.5 Beistol-Myers Squibb S.r.l.(TAXOL)

5 Prospect of Chinese Paclitaxel Market, 2021-2025

  • 5.1 Influential Factors of Chinese Paclitaxel Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Paclitaxel Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size 
  • 5.3 Forecast on Market Trend
Back to Top
전화 문의
F A Q